2024 - Harnessing Biomarker Discovery and Implementation in Clinical Trials with Novel Liquid Biopsy mRNA Gene Signatures

The integration of liquid biopsy technologies in clinical trials is revolutionizing biomarker discovery and implementation, offering non-invasive insights into tumor biology and therapeutic response. This presentation will explore Wren’s innovative approach to mRNA gene signatures, which provide a robust platform for biomarker identification and validation in diverse oncology indications, including neuroendocrine tumors, prostate cancer, colorectal cancer, lung cancer, pancreatic cancer, melanoma, and multiple myeloma.
Leveraging over 100 years of cumulative experience in biomarkers, translational research, and precision medicine, along with our extensive portfolio of over 115 patents and 60+ clinical studies across 16 countries, we have developed proprietary multigene mRNA assays that capture dynamic gene expression profiles from just 1 mL of whole blood. Our assays encompass 412 cancer-associated genes, allowing for the creation of customized gene signatures tailored to specific clinical needs. Advanced algorithms yield actionable insights with clear binary readouts and precise scoring, enabling real-time monitoring of patient responses and disease progression.
We will discuss the clinical applicability of our novel mRNA gene signatures in enhancing the drug development process, including proof of concept and mechanism studies. By demonstrating their utility in detecting minimal residual disease (MRD), predicting treatment responses, and guiding patient stratification, our assays aim to support personalized treatment strategies and improve clinical outcomes.
Join us to discover how Wren’s innovative liquid biopsy solutions can transform biomarker discovery and implementation in clinical trials, ultimately advancing precision medicine and fostering successful therapeutic development. Don’t miss this opportunity to explore the forefront of non-invasive diagnostics in biopharma!
Keywords: Biotherapeutics, Proof-of-mechanism, Gene signature, mRNA, Pharmacodynamics, Cell & Gene Therapy, Therapeutic Areas, Proof of Concept,  Oncology Drugs, Cancer, Oncology, CRO, Clinical Research, Targeted Therapy, Precision Medicine, Cancer Treatment, Drug Development